Biotech Blueprint

Moderna Flu Filing Rejected, Sanofi Replaces CEO, AbbVie Sues Over Botox Medicare Pricing – This Week in Biotech #89

CBER’s Refusal to File jolts FDA predictability, Sanofi swaps CEOs, AbbVie sues over Botox Medicare pricing, and BridgeBio’s Phase 3 win contrasts with…

Feb 13 • Katerina Roznik

7

Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars – This Week in Biotech #88

Compounded semaglutide draws FDA scrutiny as Novo Nordisk guides 2026 lower and Eli Lilly leans into a $50 Medicare copay (Jan 30-Feb 5, 2026).

Feb 6 • Katerina Roznik

4

January 2026

Regenxbio FDA Hold, Sanofi Vaccine Demand Softness, and CMS Negotiation Expansion – This Week in Biotech #87

FDA pauses two AAV programs, Sanofi reports US vaccine uptake slipping, and CMS widens negotiations to more blockbuster drugs (Jan 23-29, 2026).

Jan 30 • Katerina Roznik

8

1

Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up – This Week in Biotech #86

KEYNOTE-942 durability, plus GSK’s $2.2B RAPT food allergy deal, BMS partners Janux, Corcept's overall survival win, and Corvus posts Phase 1 eczema…

Jan 23 • Katerina Roznik

3

1

Drug Pricing Returns, AI Labs Scale Up, Gene Therapy Pushes Mainstream – This Week in Biotech #85

(Jan 9-15, 2026)

Jan 16 • Katerina Roznik

13

1

1

CDC Vaccine Schedule Shifts, Practice-Changing Phase 3 Wins, and Deal Heat – This Week in Biotech #84

Revolution takeover rumors, Amgen and Lilly pay early for platforms, plus phase 3 wins in gastroesophageal cancer, psoriasis, and hepatitis B amid a CDC…

Jan 9 • Katerina Roznik

8

Biotech Heads Into 2026: Obesity, Vaccines, Pricing & Risk — This Week in Biotech #83

A year end / new-year update on what actually moved during the holiday stretch (Dec 19, 2025 – Jan 1, 2026).

Jan 2 • Katerina Roznik

9

1

1

December 2025

CEPI Rescues Moderna’s Bird Flu Vaccine and Takeda’s Delivers in Psoriasis — This Week in Biotech #82

From pandemic preparedness to late stage clinical wins, plus key FDA approvals and trial readouts that will shape 2026 (Dec 12-18, 2025).

Dec 19, 2025 • Katerina Roznik

4

1

Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81

Plus Biohaven’s next-gen Trop2 data, Kymera’s STAT6 surge, AC Immune’s Parkinson’s signal, Mirum’s hepatitis delta bet, the CDC’s new Covid vaccine…

Dec 12, 2025 • Katerina Roznik

2

Inside NImmune’s Phase 3 Push in Ulcerative Colitis

Founder Josep Bassaganya-Riera on omilancor, a gut-restricted oral therapy, precision biomarkers in inflammatory bowel disease, and the TITAN-X AI…

Dec 10, 2025 • Katerina Roznik

5

1

1

FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80

Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec…

Dec 5, 2025 • Katerina Roznik

7

2

3

November 2025

CDC’s Autism Reversal Shocks Experts, mRNA Flu Shot Advances, Big Oncology Wins — This Week in Biotech #79

Plus Arrowhead’s first approval, Abbott buys Exact Sciences, Merck bets $9.2B on flu prevention, and fresh takeover buzz in gene editing and IBD (Nov…

Nov 21, 2025 • Katerina Roznik

9

2